All patients
age >= 60 yr age >= 65 yr corticosteroids: no corticosteroids: yes invasive ventilation non invasive oxygen subjects at risk
antiviral and associated therapy in COVID-19 mild to moderate - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results GS-US-540-5773 (Goldman), 2020 0.73 [0.37; 1.44]
Hung et al., 2020 0.47 [0.01; 24.30]
Ren, 2020 (REV) 1.00 [0.02; 55.80]
Solaymani-Dodaran, 2021 1.22 [0.66; 2.26]
0.96 [0.61 ; 1.51 ] GS-US-540-5773 (Goldman), 2020, Hung et al., 2020, Ren, 2020 (REV), Solaymani-Dodaran, 2021 4 0% 917 moderate not evaluable clinical improvementdetailed results GS-US-540-5773 (Goldman), 2020 0.79 [0.61; 1.02]
Hung et al., 2020 3.92 [1.66; 9.24]
1.67 [0.35 ; 7.98 ] GS-US-540-5773 (Goldman), 2020, Hung et al., 2020 2 92% 524 moderate not evaluable clinical improvement (14-day)detailed results GS-US-540-5773 (Goldman), 2020 1.53 [1.02; 2.29]
1.53 [1.02 ; 2.29 ] GS-US-540-5773 (Goldman), 2020 1 0% 397 NA not evaluable clinical improvement (7-day)detailed results GS-US-540-5773 (Goldman), 2020 1.46 [0.95; 2.23]
1.46 [0.95 ; 2.23 ] GS-US-540-5773 (Goldman), 2020 1 0% 397 NA not evaluable clinical improvement (time to event analysis only)detailed results GS-US-540-5773 (Goldman), 2020 0.79 [0.61; 1.02]
Hung et al., 2020 3.92 [1.66; 9.24]
Solaymani-Dodaran, 2021 0.94 [0.75; 1.17]
1.15 [0.70 ; 1.87 ] GS-US-540-5773 (Goldman), 2020, Hung et al., 2020, Solaymani-Dodaran, 2021 3 84% 904 moderate not evaluable mechanical ventilationdetailed results Solaymani-Dodaran, 2021 1.62 [0.85; 3.08]
1.62 [0.85 ; 3.08 ] Solaymani-Dodaran, 2021 1 0% 373 NA not evaluable radiologic improvement (7-day)detailed results Ren, 2020 (REV) 0.05 [0.00; 1.17]
0.05 [0.00 ; 1.17 ] Ren, 2020 (REV) 1 0% 20 NA not evaluable viral clearance detailed results Hung et al., 2020 4.37 [1.86; 10.25]
Ren, 2020 (REV) 0.04 [0.00; 0.79]
0.50 [0.00 ; 55.07 ] Hung et al., 2020, Ren, 2020 (REV) 2 88% 147 moderate not evaluable viral clearance (time to event analysis only)detailed results Hung et al., 2020 4.37 [1.86; 10.25]
4.37 [1.86 ; 10.25 ] Hung et al., 2020 1 0% 127 NA not evaluable viral clearance by day 14detailed results ELACOI (Lopinavir/ritonavir), 2020 1.84 [0.40; 8.38]
1.84 [0.40 ; 8.38 ] ELACOI (Lopinavir/ritonavir), 2020 1 0% 69 NA not evaluable viral clearance by day 7detailed results ELACOI (Lopinavir/ritonavir), 2020 1.08 [0.41; 2.89]
Ren, 2020 (REV) 0.04 [0.00; 0.79]
0.27 [0.01 ; 7.35 ] ELACOI (Lopinavir/ritonavir), 2020, Ren, 2020 (REV) 2 76% 89 moderate not evaluable ICU admissiondetailed results Solaymani-Dodaran, 2021 1.23 [0.70; 2.18]
1.23 [0.70 ; 2.18 ] Solaymani-Dodaran, 2021 1 0% 373 NA not evaluable recoverydetailed results GS-US-540-5773 (Goldman), 2020 0.81 [0.64; 1.03]
0.81 [0.64 ; 1.03 ] GS-US-540-5773 (Goldman), 2020 1 0% 397 NA not evaluable severe COVID-19 occurrencedetailed results ELACOI (Lopinavir/ritonavir), 2020 0.30 [0.07; 1.27]
0.30 [0.07 ; 1.27 ] ELACOI (Lopinavir/ritonavir), 2020 1 0% 69 NA not evaluable serious adverse eventsdetailed results Hung et al., 2020 0.23 [0.01; 7.12]
Ren, 2020 (REV) 1.00 [0.02; 55.80]
0.43 [0.03 ; 5.81 ] Hung et al., 2020, Ren, 2020 (REV) 2 0% 147 moderate not evaluable adverse eventsdetailed results Ren, 2020 (REV) 8.14 [0.35; 189.85]
8.14 [0.35 ; 189.85 ] Ren, 2020 (REV) 1 0% 20 NA not evaluable serious adverse events (SAE), anydetailed results GS-US-540-5773 (Goldman), 2020 0.50 [0.32; 0.79]
0.50 [0.32 ; 0.79 ] GS-US-540-5773 (Goldman), 2020 1 0% 397 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-01 00:08 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 90
- treatments: 545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814
- roots T: 290